Austin Kilaru, MD and Zack Meisel MD were part of a team that studied the impact of using Prescription Drug Monitoring Program (PDMP) on opioid prescriptions for patients with Sickle Cell Disease or cancer with bone metastasis. These groups often present to the ED for acute pain. Using claims data, the study team found that a state mandating the use of PDMP review was associated with a reduction in opioid prescriptions for these two groups. While these mandates are intended to decrease opioid related deaths, it is possible that they lead to the unintended consequence of undertreated pain.
Read more here.